Oryzon Genomics Sa Stock Key Fundamental Indicators
| ORYZF Stock | USD 3.60 0.24 7.14% |
As of the 4th of February, Oryzon Genomics holds the Coefficient Of Variation of 37419.7, risk adjusted performance of 0.006, and Variance of 1.52. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oryzon Genomics, as well as the relationship between them. Please check Oryzon Genomics SA risk adjusted performance, variance, as well as the relationship between the Variance and kurtosis to decide if Oryzon Genomics SA is priced some-what accurately, providing market reflects its current price of 3.6 per share. Given that Oryzon Genomics has variance of 1.52, we recommend you to check out Oryzon Genomics SA's recent market performance to make sure the company can sustain itself at a future point.
Oryzon Genomics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Oryzon Genomics' valuation are provided below:Oryzon Genomics SA does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Oryzon |
Oryzon Genomics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Oryzon Genomics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Oryzon Genomics.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Oryzon Genomics on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Oryzon Genomics SA or generate 0.0% return on investment in Oryzon Genomics over 90 days. Oryzon Genomics is related to or competes with Silence Therapeutics, Genfit SA, Transgene, Hansa Biopharma, JW (Cayman), and NervGen Pharma. Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetic... More
Oryzon Genomics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Oryzon Genomics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Oryzon Genomics SA upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 7.14 |
Oryzon Genomics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oryzon Genomics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Oryzon Genomics' standard deviation. In reality, there are many statistical measures that can use Oryzon Genomics historical prices to predict the future Oryzon Genomics' volatility.| Risk Adjusted Performance | 0.006 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.08) | |||
| Treynor Ratio | (0.05) |
Oryzon Genomics February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.006 | |||
| Market Risk Adjusted Performance | (0.04) | |||
| Mean Deviation | 0.2164 | |||
| Coefficient Of Variation | 37419.7 | |||
| Standard Deviation | 1.23 | |||
| Variance | 1.52 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | (0.08) | |||
| Treynor Ratio | (0.05) | |||
| Maximum Drawdown | 7.14 | |||
| Skewness | 0.2645 | |||
| Kurtosis | 32.53 |
Oryzon Genomics SA Backtested Returns
At this point, Oryzon Genomics is somewhat reliable. Oryzon Genomics SA maintains Sharpe Ratio (i.e., Efficiency) of close to zero, which implies the firm had a close to zero % return per unit of risk over the last 3 months. We have found twenty technical indicators for Oryzon Genomics SA, which you can use to evaluate the volatility of the company. Please check Oryzon Genomics' Risk Adjusted Performance of 0.006, coefficient of variation of 37419.7, and Variance of 1.52 to confirm if the risk estimate we provide is consistent with the expected return of 0.0035%. The company holds a Beta of 0.13, which implies not very significant fluctuations relative to the market. As returns on the market increase, Oryzon Genomics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Oryzon Genomics is expected to be smaller as well. Oryzon Genomics SA right now holds a risk of 1.27%. Please check Oryzon Genomics SA variance, as well as the relationship between the kurtosis and price action indicator , to decide if Oryzon Genomics SA will be following its historical price patterns.
Auto-correlation | -0.28 |
Weak reverse predictability
Oryzon Genomics SA has weak reverse predictability. Overlapping area represents the amount of predictability between Oryzon Genomics time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Oryzon Genomics SA price movement. The serial correlation of -0.28 indicates that nearly 28.0% of current Oryzon Genomics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.28 | |
| Spearman Rank Test | -0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Oryzon Genomics SA has a Return On Equity of -0.0685. This is 99.71% lower than that of the Healthcare sector and 99.81% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 77.9% lower than that of the firm.
Oryzon Genomics SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Oryzon Genomics's current stock value. Our valuation model uses many indicators to compare Oryzon Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oryzon Genomics competition to find correlations between indicators driving Oryzon Genomics's intrinsic value. More Info.Oryzon Genomics SA is regarded fifth in return on equity category among its peers. It also is regarded fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Oryzon Genomics' earnings, one of the primary drivers of an investment's value.Oryzon Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oryzon Genomics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Oryzon Genomics could also be used in its relative valuation, which is a method of valuing Oryzon Genomics by comparing valuation metrics of similar companies.Oryzon Genomics is currently under evaluation in return on equity category among its peers.
Oryzon Fundamentals
| Return On Equity | -0.0685 | |||
| Return On Asset | -0.0419 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.72) % | |||
| Current Valuation | 106.94 M | |||
| Shares Outstanding | 55.26 M | |||
| Shares Owned By Insiders | 18.04 % | |||
| Shares Owned By Institutions | 0.72 % | |||
| Price To Book | 1.77 X | |||
| Price To Sales | 13.40 X | |||
| Gross Profit | 9.87 M | |||
| EBITDA | (6.58 M) | |||
| Net Income | (4.69 M) | |||
| Cash And Equivalents | 28.72 M | |||
| Cash Per Share | 0.54 X | |||
| Total Debt | 10.35 M | |||
| Debt To Equity | 0.25 % | |||
| Current Ratio | 3.76 X | |||
| Book Value Per Share | 1.35 X | |||
| Cash Flow From Operations | (3.63 M) | |||
| Earnings Per Share | (0.09) X | |||
| Number Of Employees | 43 | |||
| Beta | 1.02 | |||
| Market Capitalization | 143.68 M | |||
| Total Asset | 95.38 M | |||
| Z Score | 7.8 | |||
| Net Asset | 95.38 M |
About Oryzon Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oryzon Genomics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oryzon Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oryzon Genomics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. The company was founded in 2000 and is based in Cornell de Llobregat, Spain. Oryzon Genomics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 43 people.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Oryzon Pink Sheet
Oryzon Genomics financial ratios help investors to determine whether Oryzon Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oryzon with respect to the benefits of owning Oryzon Genomics security.